Skip to Main Content
Phase COVID-Pilot

Magnetic Resonance Imaging Biomarkers: A tool to study central nervous system disease (MBAT)

  • Study HIC#:2000031278
  • Last Updated:11/11/2022

Initial MRI studies of post-COVID individuals have revealed small changes in the brains of patients with neurologic symptoms. The scientific community is unsure what these changes mean and how long they last. In our pilot study, we hope to identify consistent, measurable changes on MRI in patients who have neurological symptoms, particularly cognitive impairment, and a history of COVID-19. We plan to follow these changes over time. Identifying consistent markers on MRI over time will allow us to better understand the neurological effects of these diseases.

  • Start Date01/12/2022
  • End Date09/30/2026

Eligibility Criteria

  • Adults only; 
  • Laboratory documented COVID-19 infection (PCR, rapid test, or pre-vaccine positive antibody test); 
  • Persistent cognitive impairment post-COVID

Sub-Investigators

For more information about this study, contact:

Or contact the Help us Discover team on: